Sucampo Pharmaceuticals, Inc.  

(Public, NASDAQ:SCMP)   Watch this stock  
Find more results for SCMP
11.38
-0.03 (-0.26%)
Real-time:   9:59AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.31 - 11.45
52 week 9.59 - 29.67
Open 11.39
Vol / Avg. 2,647.00/419,200.00
Mkt cap 512.10M
P/E 23.03
Div/yield     -
EPS 0.49
Shares 45.64M
Beta 1.41
Inst. own 44%
Aug 3, 2016
Q2 2016 Sucampo Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Aug 3, 2016
Q2 2016 Sucampo Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Jul 12, 2016
Sucampo Pharmaceuticals Inc at Cantor Fitzgerald Healthcare Conference - Webcast
Jun 22, 2016
Sucampo Pharmaceuticals Inc at ROTH Healthcare Day
Jun 7, 2016
Sucampo Pharmaceuticals Inc at Jefferies Healthcare Conference
Jun 2, 2016
Sucampo Pharmaceuticals Inc Annual Shareholders Meeting
May 27, 2016
Sucampo Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
May 24, 2016
Sucampo Pharmaceuticals Inc at UBS Global Healthcare Conference
May 10, 2016
Sucampo Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 4, 2016
Q1 2016 Sucampo Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -8.59% 21.79%
Operating margin -1.07% 29.02%
EBITD margin - 36.12%
Return on average assets -3.59% 11.15%
Return on average equity -17.38% 39.55%
Employees 159 -
CDP Score - -

Address

805 King Farm Blvd Ste 550
ROCKVILLE, MD 20850-6162
United States - Map
+1-301-9613400 (Phone)
+1-301-9613440 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009.

Officers and directors

Peter S. Greenleaf Chairman of the Board, Chief Executive Officer
Age: 45
Bio & Compensation  - Reuters
Andrew P. Smith Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Max Donley Executive Vice President of Human Resources
Age: 46
Bio & Compensation  - Reuters
Thomas J. Knapp Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
Matthias Alder LL.M Executive Vice President - Business Development & Licensing
Age: 50
Bio & Compensation  - Reuters
Stanley G. Miele Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
Age: 51
Bio & Compensation  - Reuters
Peter A. Kiener Chief Scientific Officer
Age: 62
Bio & Compensation  - Reuters
Peter Lichtlen M.D., Ph.D. Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
John H. Johnson Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Daniel P. Getman Ph.D. Director
Age: 59
Bio & Compensation  - Reuters